durvalumab,ipilimumab,nivolumab
astrazeneca,orpathys,bms
['nivo', 'import', 'cm214', 'calypso', 'rcc,(-irccs),(-srcc),(-urcc)']
dr. presentes the results of calypso trial in vegfr tki refractory rcc patients. imo, one important take away is that ctla4 inhibition seems to be very relevant in rcc, and in this case emphasizing ipi-nivo (cm214) in the 1st line. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer